Welcome to our dedicated page for Aerie Pharmaceut news (Ticker: AERI), a resource for investors and traders seeking the latest updates and insights on Aerie Pharmaceut stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Aerie Pharmaceut's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Aerie Pharmaceut's position in the market.
Aerie Pharmaceuticals (NASDAQ: AERI) announced its participation in the virtual Cantor Global Healthcare Conference on September 28, 2021, at 8:40 a.m. ET. Interim Executive Chairman Benjamin F. McGraw, III, and Chief R&D Officer David A. Hollander will discuss company updates and an overview. The live webcast can be accessed through Aerie's website and will be available for replay for 10 business days.
Aerie focuses on innovative therapies for glaucoma and ocular diseases, with products like Rhopressa® and Rocklatan® launched in the U.S. in 2018 and 2019, respectively.
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) announced a leadership transition effective September 17, 2021, as Vicente Anido, PhD, steps down as Chairman and CEO. Benjamin F. McGraw, III, Pharm.D. is appointed as Interim Executive Chairman while the search for a new CEO begins. Dr. McGraw expressed gratitude for Dr. Anido's contributions, highlighting the company's product portfolio of Rhopressa and Rocklatan. Aerie aims to separate the chairman and CEO roles in the future to strengthen governance.
Aerie Pharmaceuticals (NASDAQ:AERI) has appointed Dr. Erik Pacyniak as Director of Toxicology, reporting to Dr. Jeff White. Dr. Pacyniak will manage nonclinical toxicology and drug disposition. He previously held a position at Mycovia Pharmaceuticals. As part of his compensation, he will receive 16,900 stock options vesting over four years, contingent upon employment. This award was approved by Aerie's independent directors under Nasdaq Listing Rule 5635(c)(4).
Aerie Pharmaceuticals (NASDAQ:AERI) announced positive topline results from its Phase 2b clinical study, COMET-1, for AR-15512, an ophthalmic solution aimed at treating dry eye disease. The study included 369 patients across three dosing arms, revealing significant efficacy in the 0.003% BID formulation, which will progress to Phase 3 trials. Key endpoints such as ocular discomfort showed statistical significance (p=0.028), with safety data indicating 95% of adverse events were mild. A conference call to discuss results is scheduled for September 15, 2021.
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) has appointed Carolyn McAuliffe as the Senior Director of Communications, effective immediately. She will report to Tad Heitmann, Aerie's VP of Marketing, and oversee marketing and medical communications. McAuliffe will receive 16,900 stock options, vesting over four years, as part of her compensation. This award complies with Nasdaq Listing Rule 5635(c)(4). Aerie focuses on developing treatments for open-angle glaucoma and other ocular diseases, with products like Rhopressa® and Rocklatan® already on the market.
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company, announced that CEO Vicente Anido, Jr., Ph.D., will participate in two upcoming virtual investor conferences. The events include the Citi 16th Annual BioPharma Conference on September 9, 2021, at 8:50 a.m. ET, focusing on next-generation retinal therapeutics, and the Wells Fargo Healthcare Conference on September 10, 2021, at 8:40 a.m. ET, featuring a fireside chat. Live webcasts of these discussions will be available on Aerie's website, with replays accessible for 10 business days.
Aerie Pharmaceuticals (NASDAQ:AERI) announces the appointment of Michael Bradley as Senior Director of Manufacturing, overseeing the Athlone, Ireland facility. Bradley brings significant experience from positions at Norbrook and Zoetis. In conjunction with his appointment, he is awarded 16,900 stock options vesting over four years, approved by independent directors under Nasdaq Listing Rule 5635(c)(4). Aerie specializes in innovative therapies for open-angle glaucoma and related eye diseases, with notable products including Rhopressa® and Rocklatan®.
Aerie Pharmaceuticals (NASDAQ: AERI) announced that Dr. Casey C. Kopczynski, Chief Scientific Officer, will participate in a virtual panel discussion at the H.C. Wainwright Ophthalmology Conference. This event, titled “What are the Greatest Unmet Needs Facing Ophthalmology Today?”, is scheduled for August 17, 2021, at 9:00 a.m. Eastern Time. Interested attendees can access the live webcast via Aerie's website, with a replay available for 10 business days.
Aerie specializes in ophthalmic therapies for conditions like open-angle glaucoma and ocular surface diseases.
Aerie Pharmaceuticals (NASDAQ:AERI) reported strong second quarter 2021 results, with a 51% growth in net revenues and 31% growth in bottle volumes for its glaucoma franchise compared to Q2 2020. Net revenue per bottle increased to $89, driven by renegotiated wholesaler fees. The company ended the quarter with $188 million in cash, down from $23 million in operational burn last year. Despite positive results, Aerie has not provided full-year guidance due to uncertainties from the pandemic. The company aims to advance its pipeline, including upcoming Phase 2b and Phase 3 trials.
Aerie Pharmaceuticals (NASDAQ: AERI) will release its Q1 2021 financial results after market close on August 4, 2021. A live conference call and webcast will follow at 5:00 PM ET to discuss the results and provide a general business update. Aerie is focused on developing innovative therapies for open-angle glaucoma and other ocular diseases, having launched its first product, Rhopressa®, in April 2018, and Rocklatan® in May 2019. The company is also expanding its global reach and developing additional candidates in ophthalmology.
